Role of hypoxia-inducible factor-1α and survivin in breast cancer recurrence and prognosis

Cao, Qian; Mushajiang, Munire; Tang, Cheng-qiong; Ai, Xiu-Qing

doi:10.1016/j.heliyon.2023.e14132

Cited by 4 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can also promote the recruitment and expansion of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), both of which contribute to the immunosuppression [20]. In addition, hypoxia may upregulate the expression of PD-L1 in the hypoxic TME [21] and induce the production of exosomes and macrovesicles in breast cancer cells through HIF-dependent RAB22A expression, which can stimulate invasion and metastasis with poor overall survival rates [22].…”

Section: Tumor-induced Hypoxiamentioning

confidence: 99%

Breaking Barriers: The Promise and Challenges of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer

Said,

Ibrahim

2024

Biomedicines

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is a highly aggressive malignancy with pronounced immunogenicity, exhibiting rapid proliferation and immune cell infiltration into the tumor microenvironment. TNBC’s heterogeneity poses challenges to immunological treatments, inducing resistance mechanisms in the tumor microenvironment. Therapeutic modalities, including immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and CTLA-4, are explored in preclinical and clinical trials. Promising results emerge from combining ICIs with anti-TGF-β and VISTA, hindering TNBC tumor growth. TNBC cells employ complex evasion strategies involving interactions with stromal and immune cells, suppressing immune recognition through various cytokines, chemokines, and metabolites. The recent focus on unraveling humoral and cellular components aims to disrupt cancer crosstalk within the tumor microenvironment. This review identifies TNBC’s latest resistance mechanisms, exploring potential targets for clinical trials to overcome immune checkpoint resistance and enhance patient survival rates.

show abstract

Section: Tumor-induced Hypoxiamentioning

confidence: 99%

Breaking Barriers: The Promise and Challenges of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer

Said,

Ibrahim

2024

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Relevant studies ( 8 – 10 ) showed that the current situation of breast cancer in Xinjiang is different from that in other regions, with such features as lower incidence rate, luminal breast cancer appearing more frequently, and women aged 45–55 having a higher risk of developing this disease. At present, there have been many studies evaluating the prognostic risk factors of patients with breast cancer in Xinjiang ( 11 – 14 ); for instance, Shan et al. ( 11 ) investigated the clinicopathological features and prognostic characteristics of patients with triple-negative breast cancer in Xinjiang, based on clinical information for 319 patients.…”

Section: Introductionmentioning

confidence: 99%

“…Cao et al. ( 14 ) evaluated the association of hypoxia-inducible factor-1α and survivin with breast cancer prognosis in breast cancer patients. However, the sample size of some studies was relatively small ( 11 , 12 ), and those studies were mainly focus on exploring the impact of molecular subtypes or gene expression on the prognosis of breast cancer patients ( 11 , 13 , 14 ).…”

Section: Introductionmentioning

confidence: 99%

“…( 14 ) evaluated the association of hypoxia-inducible factor-1α and survivin with breast cancer prognosis in breast cancer patients. However, the sample size of some studies was relatively small ( 11 , 12 ), and those studies were mainly focus on exploring the impact of molecular subtypes or gene expression on the prognosis of breast cancer patients ( 11 , 13 , 14 ). On the other hand, it is necessary to follow up a large number of research subjects over the long-term in survival analysis, which may inevitably cause certain omissions in the process of data collection.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessing of case–cohort design: a case study for breast cancer patients in Xinjiang, China

Wu,

Zhang,

Gao

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveTo assess the effectiveness and clinical value of case–cohort design and determine prognostic factors of breast cancer patients in Xinjiang on the basis of case–cohort design.MethodsThe survival data with different sample characteristics were simulated by using Cox proportional risk models. To evaluate the effectiveness for the case–cohort, entire cohort, and simple random sampling design by comparing the mean, coefficient of variation, etc., of covariate parameters. Furthermore, the prognostic factors of breast cancer patients in Xinjiang were determined based on case–cohort sampling designs. The models were comprehensively evaluated by likelihood ratio test, the area under the receiver operating characteristic curve (AUC), and Akaike Information Criterion (AIC).ResultsIn a simulations study, the case–cohort design shows better stability and improves the estimation efficiency when the censored rate is high. In the breast cancer data, molecular subtypes, T-stage, N-stage, M-stage, types of surgery, and postoperative chemotherapy were identified as the prognostic factors of patients in Xinjiang. These models based on the different sampling designs both passed the likelihood ratio test (p<0.05). Moreover, the model constructed under the case–cohort design had better fitting effect (AIC=3,999.96) and better discrimination (AUC=0.807).ConclusionSimulations study confirmed the effectiveness of case–cohort design and further determined the prognostic factors of breast cancer patients in Xinjiang based on this design, which presented the practicality of case–cohort design in actual data.

show abstract

The prognostic role of survivin expression in breast cancer: A systematic review and meta-analysis

Bolat Kucukzeybek,

Kucukzeybek,

Basbinar

et al. 2024

Medicine

View full text Add to dashboard Cite

Background: Breast cancer is a heterogeneous condition with variations in histopathological, genomic, and biological characteristics. Although clinicopathological prognostic factors and gene expression profiles are commonly used to guide treatment decisions in patients with breast cancer, there is still a need for new prognostic markers. One potential marker is survivin, a protein belonging to the apoptosis inhibitor family. However, studies examining the relationship between survivin and prognosis in breast cancer have yielded inconsistent results. This study aimed to evaluate the impact of survivin expression on the prognosis of breast cancer patients through a meta-analysis. Methods: Studies evaluating survivin expression were sourced from the PubMed, Embase, and Cochrane databases. We conducted a meta-analysis based on full-text articles that evaluated the relationship between survivin expression and survival by immunochemistry or polymerase chain reaction. The studies were initially divided into 2 groups based on the evaluation of overall survival (OS) and disease-free survival (DFS). Subsequently, each group was further categorized according to the method used to detect survivin expression. Statistical analyses for this study were conducted using Stata and JAMOVI. Results: After screening with keywords, we identified 24 retrospective studies evaluating OS and 15 retrospective studies evaluating DFS, which were included in the analysis. We found that the studies in the meta-analysis were not heterogeneous, and this remained consistent when categorizing the groups by survivin expression detection. Survivin expression was associated with OS (HR 1.23, 95% CI 0.81–1.65) and DFS (HR 0.89, CI 0.42–1.36), indicating poor prognosis. This significant relationship between survivin expression and survival persisted when the studies were categorized by the detection method, either immunohistochemistry or polymerase chain reaction. Conclusion: In this study, we evaluated the prognostic significance of survivin expression in patients with breast cancer through a meta-analysis. These results support the use of survivin expression as a prognostic marker in breast cancer, potentially guiding treatment decisions.

show abstract

Role of hypoxia-inducible factor-1α and survivin in breast cancer recurrence and prognosis

Cited by 4 publications

References 30 publications

Breaking Barriers: The Promise and Challenges of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer

Breaking Barriers: The Promise and Challenges of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer

Assessing of case–cohort design: a case study for breast cancer patients in Xinjiang, China

The prognostic role of survivin expression in breast cancer: A systematic review and meta-analysis

Contact Info

Product

Resources

About